Anti-Cancer Drug Discovery & Development Conference to Feature Latest Industry Advances in Princeton, NJ, June 11 & 12

Apr 20, 2001, 01:00 ET from Strategic Research Institute

    PRINCETON, N.J., April 20 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research on novel protein kinase inhibitors, therapeutic
 antibodies, angiogenesis, proteasome inhibitors and applied genomic
 technologies at the pre-clinical and clinical stages will be the focus of the
 "2nd International Anti-Cancer Drug Discovery & Development Summit" taking
 place in Princeton, NJ on June 11-12, 2001, announces Strategic Research
 Institute.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in cancer,
 4) angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Presenting papers on behalf of the industry will be Hoffmann-La Roche,
 Novartis, Merck, Schering-Plough, Wyeth-Ayerst, Bristol-Myers Squibb, Amgen,
 Eli Lilly, Millennium Pharmaceuticals, Celera Genomics, Medarex, ILEX
 Oncology, ImClone Systems, Eos Biotechnology, Biomira, Cytokinetics, Ceretek
 while Georgetown University and Columbia University will represent the
 academic community.
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at jliong@srinstitute.com
 or 212-967-0095, x243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 

SOURCE Strategic Research Institute
    PRINCETON, N.J., April 20 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research on novel protein kinase inhibitors, therapeutic
 antibodies, angiogenesis, proteasome inhibitors and applied genomic
 technologies at the pre-clinical and clinical stages will be the focus of the
 "2nd International Anti-Cancer Drug Discovery & Development Summit" taking
 place in Princeton, NJ on June 11-12, 2001, announces Strategic Research
 Institute.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in cancer,
 4) angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Presenting papers on behalf of the industry will be Hoffmann-La Roche,
 Novartis, Merck, Schering-Plough, Wyeth-Ayerst, Bristol-Myers Squibb, Amgen,
 Eli Lilly, Millennium Pharmaceuticals, Celera Genomics, Medarex, ILEX
 Oncology, ImClone Systems, Eos Biotechnology, Biomira, Cytokinetics, Ceretek
 while Georgetown University and Columbia University will represent the
 academic community.
     To receive the full agenda and/or register for the conference, please
 contact Jon E. Liong of Strategic Research Institute at jliong@srinstitute.com
 or 212-967-0095, x243 (please include name, corporate affiliation, mailing
 address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 SOURCE  Strategic Research Institute